Palatin narrows annual loss but warns that further funding is needed

Palatin Technologies ($PTN) reported fiscal 2026 collaboration and license revenue of $13.2 million, against none a year earlier, and reduced its net loss to $8.4 million from $17.3 million. Approximately $9.4 million of revenue related to Boehringer Ingelheim, while $3.8 million arose from non-cash debt cancellation under the Altanispac licensing agreement.

The improved accounting result does not remove liquidity pressure. Palatin used $13.5 million in operating cash and ended the year with $7.5 million of cash. Management said existing resources would not fund at least twelve months of operations after issuance of the accounts, creating substantial going-concern doubt. Planned first-in-human studies of injectable and oral obesity candidates during 2027 depend on additional financing; preclinical findings do not establish effectiveness or tolerability in patients.

Sources:

• Palatin company release via PR Newswire / StockTitan
• Palatin earlier exchange-transfer announcement — identity verification only